OKYO Pharma Limited (OKYO) is a Biotechnology company in the Healthcare sector, listed on Nasdaq. This page provides the complete earnings calendar, dividend schedule, and financial data for OKYO Pharma Limited in 2026. The next earnings report is expected on December 2, 2026.
Next earnings date
02 Dec 2026
In 104 days
EPS estimate
-0.06
Revenue estimate
0
Past earnings
Latest earnings analysis
OKYO Pharma Limited missed consensus estimates in its latest earnings report, posting EPS of $-0.15 versus an expected $-0.08, while revenue of $0.00 met estimates. In the prior report, EPS came in ahead of expectations.
No dividend history available.
OKYO Pharma Limited, a preclinical biopharmaceutical company, engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead product includes OK-101 for the treatment of dry eye disease. The company is also developing OK-201, a bovine adrenal medulla, lipidated-peptide preclinical analogue candidate for the treatment of neuropathic ocular pain. OKYO Pharma Limited was incorporated in 2007 and is headquartered in London, the United Kingdom.
OKYO Pharma Limited (OKYO) is scheduled to report earnings on December 2, 2026.
OKYO Pharma Limited (OKYO) last reported earnings on July 20, 2026.
OKYO Pharma Limited (OKYO) is listed on Nasdaq.
We use cookies to make our website work and improve your experience. With your consent, we also use cookies for analytics and advertising.